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ORIGINAL INVESTIGATION
Symmetric and asymmetric 
dimethylarginine as risk markers 
of cardiovascular disease, all-cause mortality 
and deterioration in kidney function in persons 
with type 2 diabetes and microalbuminuria
Emilie H. Zobel1* , Bernt Johan von Scholten1, Henrik Reinhard1, Frederik Persson1, Tom Teerlink2, 
Tine W. Hansen1, Hans‑Henrik Parving3, Peter K. Jacobsen4 and Peter Rossing1,5
Abstract 
Background: To evaluate symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) as risk 
markers of cardiovascular disease, all‑cause mortality and deterioration in renal function in a well characterised type 2 
diabetic population with microalbuminuria and without symptoms of coronary artery disease.
Methods: 200 participants followed for 6.1 years. SDMA and ADMA were measured at baseline. Endpoints included 
(1) composite cardiovascular endpoint (n = 40); (2) all‑cause mortality (n = 26); and (3) decline in eGFR of >30% 
(n = 42). Cox models were unadjusted and adjusted for traditional risk factors (sex, age, systolic blood pressure, LDL‑
cholesterol, smoking,  HbA1c, creatinine and urinary albumin excretion rate). To assess if SDMA or ADMA improved risk 
prediction beyond traditional risk factors we calculated c statistics and relative integrated discrimination improvement 
(rIDI). C statistic (area under the curve) quantifies the model’s improved ability to discriminate events from non‑events. 
rIDI quantifies the increase in separation of events and non‑events on a relative scale.
Results: Higher SDMA was associated with increased risk of all three endpoints (unadjusted: p ≤ 0.001; adjusted: 
p ≤ 0.02). Higher ADMA was associated with all‑cause mortality (unadjusted: p = 0.002; adjusted: p = 0.006), but 
not cardiovascular disease or decline in eGFR (p ≥ 0.29).The c statistic was not significant for any of the endpoints 
for either SDMA or ADMA (p ≥ 0.10). The rIDI for SDMA was 15.0% (p = 0.081) for the cardiovascular endpoint, 52.5% 
(p = 0.025) for all‑cause mortality and 48.8% (p = 0.007) for decline in eGFR; for ADMA the rIDI was 49.1% (p = 0.017) 
for all‑cause mortality.
Conclusion: In persons with type 2 diabetes and microalbuminuria higher SDMA was associated with incident cardi‑
ovascular disease, all‑cause mortality and deterioration in renal function. Higher ADMA was associated with all‑cause 
mortality. SDMA and ADMA significantly improved risk prediction for all‑cause mortality, and SDMA for deterioration 
in renal function beyond traditional risk factors.
Keywords: Microalbuminuria, Type 2 diabetes, Cardiovascular disease, Macrovascular disease,  
Symmetric dimethylarginine, Asymmetric dimethylarginine
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Background
Cardiovascular disease is a major complication in type 2 
diabetes despite multifactorial intervention [1, 2]. There 
is an ongoing search for biomarkers that can improve risk 
prediction in type 2 diabetes. Symmetric and asymmet-
ric dimethylarginine (SDMA and ADMA, respectively) 
are dimethylarginines structurally related to l-arginine. 
Due to their biological functions, both markers have 
been explored as cardiovascular biomarkers. ADMA 
is considered an independent risk factor for cardiovas-
cular disease and mortality in a range of populations at 
different levels of cardiovascular risk [3, 4] and in type 
1 diabetes [5, 6]. Although elevated levels of ADMA in 
persons with type 2 diabetes and macrovascular disease 
have been reported in cross sectional studies [7, 8], there 
are conflicting results concerning the prognostic value [9, 
10]. It is unknown whether associations seen for ADMA 
extend to the structural isomer SDMA. A recent meta-
analysis demonstrated that higher SDMA is a risk factor 
for cardiovascular disease and mortality in different pop-
ulations, with the strongest associations observed in the 
general population [3]. This meta-analysis did not report 
results for any diabetic cohorts. Studies of SDMA in type 
2 diabetes are few; however a cross sectional study dem-
onstrated higher SDMA in persons with cardiovascular 
disease [8].
The use of metabolomics has been instrumental in 
identifying new biomarkers of chronic kidney disease 
such as the dimethylarginines [11]. ADMA and SDMA 
were originally reported to accumulate in renal failure 
[12] and may also be risk factors for deterioration in renal 
function in type 2 diabetes. ADMA is an outcome predic-
tor of acute kidney injurie [13] and has been reported to 
predict an increased rate of decline in GFR and develop-
ment of end stage renal disease in type 1 diabetes [5] and 
has been related to presence of renal dysfunction in type 
2 diabetes [8, 14].
We evaluated SDMA and ADMA as risk markers of 
cardiovascular disease, all-cause mortality and decline 
in renal function in a well characterised type 2 diabetic 
population with microalbuminuria and without symp-
toms suggestive of coronary artery disease. Moreover, we 
assessed whether SDMA and ADMA improved risk pre-
diction beyond traditional risk factors using c statistics 
and integrated discrimination improvement (IDI).
Methods
Participants
200 participants were recruited from the outpatient clinic 
at Steno Diabetes Center Copenhagen. Inclusion criteria 
were (1) type 2 diabetes according to WHO criteria; (2) 
no history of coronary artery disease or symptoms sug-
gestive of cardiac disease (assessed from interviews with 
the patient and patient records); and (3) persistent uri-
nary albumin excretion rate (UAER) >30 mg/24 h (in two 
out of three consecutive measurements). 613 consecutive 
patients were invited by letter to participate in the study. 
72 patients declined the invitation. 341 patients were 
excluded. Exclusion criteria were (1) normal or non-per-
sistent elevated UAER (n = 52); (2) symptoms/signs or a 
history of cardiac disease, including Q waves in 12-lead 
ECGs (n  =  180); (3) relative contraindications to com-
puted tomography angiography or coronary angiography, 
including abnormal plasma creatinine levels (n = 86); (4) 
physical or mental disability (n = 10); or (5) malignancy 
(n = 13) [15].
At the time the study was designed, in the absence of 
data from other prospective studies using the biomark-
ers in a type 2 diabetic population, the study was con-
ducted as an exploratory study using the sample size 
available.
Biochemical and other measures
Plasma concentrations of SDMA and ADMA were deter-
mined simultaneously by high-performance liquid chro-
matography with fluorescence detection as previously 
described [16], using modified chromatographic separa-
tion conditions [17]. For both SDMA and ADMA, the 
intra- and interassay coefficients of variation were <2 
and <4%, respectively. Blood was centrifuged immedi-
ately after collection, and plasma was frozen at −80  °C 
and stored in a research biobank for analysis immediately 
after the last participant was examined. Thus the maxi-
mal storage time of the samples prior to analysis of both 
biomarkers was 13  months. Quantification of SDMA 
and ADMA was available for all participants. UAER was 
measured in 24-h collected urine samples by enzyme 
immunoassay (Vitros, Raritan, NJ, USA). Current smok-
ing was defined as one or more cigarettes, cigars or pipes 
per day. Brachial blood pressure was measured twice 
after 10  min rest using an appropriate cuff size, and 
averaged.
Follow up
All participants were traced through the Danish National 
Death Register and the Danish National Health Register 
on the 1st of January 2014. No participants were lost to 
follow-up. Definitions of the three predefined endpoints 
have previously been described [18, 19]. The combined 
cardiovascular endpoint was defined as cardiovascular 
mortality, stroke, ischaemic cardiovascular disease and 
heart failure. For participants with multiple events, only 
the first was included. Moreover, we followed 177 out 
of the 200 (88.5%) participants originally included with 
yearly measurements of plasma creatinine used for cal-
culations of eGFR applying the Chronic Kidney Disease 
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Epidemiology Collaboration (CKD-epi) equation [20]. 
The renal endpoint was defined as decline in eGFR >30% 
(evaluated as change from baseline to the last available 
measurement), as proposed by Coresh et al. [21].
Statistical analyses
Symmetric dimethylarginine, ADMA and UAER were 
non-normally distributed and are summarized as 
median with interquartile range (IQR), and log10 trans-
formed in all analyses. All other continuous variables 
are given as mean ±  standard deviation (SD) and cat-
egorical variables as total numbers with corresponding 
percentages.
We used t-test for continuous variables and Χ2 test for 
categorical variables to test for differences in potential 
confounders in the population categorized according to 
SDMA and ADMA above or below the median.
First, we applied Cox proportional hazards analysis to 
compute the unadjusted hazard ratios (HR)’s per 1 SD 
increment of SDMA and ADMA with 95% confidence 
interval (CI) for the three endpoints, next we calculated 
HR’s adjusted for traditional cardiovascular risk factors 
based on existing evidence: sex, age, systolic blood pres-
sure, LDL-cholesterol, smoking,  HbA1c, plasma creati-
nine and UAER.
To quantify the added predictive value of SDMA and 
ADMA, we calculated receiver operating characteristic 
(ROC) curves based on logistic regression models and 
applied c statistics to compare the area under the curve 
(AUC) for the model including traditional cardiovas-
cular risk factors and the AUC for the model including 
traditional cardiovascular risk factors plus SDMA and 
ADMA, respectively. For the significant associations in 
the adjusted models, we further illustrated the risk infor-
mation with ROC-curves. We then calculated the IDI, a 
measure suggested by Pencina et al. [22] as a more pow-
erful method to demonstrate improved diagnostic perfor-
mance of a biomarker. To ease the interpretation, relative 
IDI (rIDI) is provided and reported as a percentage. rIDI 
is defined as the increase in discrimination slope when 
adding SDMA or ADMA respectively to traditional risk 
factors divided by the slope of the model including only 
the traditional risk factors [22].
Finally, we applied the Kaplan–Meier failure function 
to compare the risks of the combined cardiovascular 
endpoint, all-cause mortality and deterioration in renal 
function according to the median level of SDMA, and to 
compare the risks of all-cause mortality according to the 
median level of ADMA.
A two-tailed p value of <0.05 was considered signifi-
cant. Statistical analyses were performed using SPSS for 
Windows (version 23.0, Chicago, IL, USA) and SAS soft-
ware (version 9.4, SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Baseline characteristics of all the 200 participants and 
categorized according to the median level of SDMA and 
ADMA respectively are listed in Table  1. Participants 
with high SDMA were older, had higher plasma creati-
nine, lower eGFR and systolic blood pressure compared 
to participants with low SDMA. Participants with high 
ADMA levels were older, with higher UAER and plasma 
creatinine and lower eGFR compared to participants 
with low ADMA. All participants were receiving multi-
factorial treatment on top of oral antidiabetic medication 
or insulin including antihypertensive drugs (99%), renin–
angiotensin–aldosterone system-blocking treatment 
(98%), statins (95%) and aspirin (92%). Figure 1 illustrates 
the positive correlation between SDMA and ADMA 
 (R2 = 0.20; p < 0.001).
Incidence of cardiovascular disease, all‑cause mortality 
and decline in eGFR
Median (IQR) follow up for the combined cardiovascular 
endpoint and mortality was 6.1 (5.9–6.6) years.
Combined cardiovascular endpoint (n = 40)
11 fatal cardiovascular events (two cases of acute myo-
cardial infarction, one case of ischaemic cardiovascular 
disease, six sudden and otherwise unexplained deaths 
and two cases of heart failure) and 29 non-fatal cardio-
vascular events (three cases of acute myocardial infarc-
tion, three strokes, 19 cases of ischaemic cardiovascular 
disease, four cases of heart failure all leading to hospital 
admission).
All‑cause mortality (n = 26)
11 related to cardiovascular disease, 9 cancer-related and 
6 related to other causes.
Decline in eGFR >30% (n = 42)
Median (IQR) follow up was 4.9 (3.8–5.4) years. In 23 
participants the decline was confirmed in two or more 
measurements. In 17 participants the decline was seen at 
the final study visit and could therefore not be confirmed. 
No participants progressed to dialysis or end-stage renal 
disease during follow up.
The distribution of time to event for the combined car-
diovascular endpoint, all-cause mortality and deteriora-
tion in renal function is shown in Additional file 1: Figure 
S1.
Symmetric dimethylarginine as a risk marker
Table  2 shows the association between SDMA and car-
diovascular disease, all-cause mortality, and decline in 
eGFR. Higher SDMA was associated with all endpoints 
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in both unadjusted (p ≤  0.001) and adjusted (p ≤  0.02) 
analyses.
As shown in Fig.  2a, b in relation to the composite 
cardiovascular endpoint, the AUC increased from 0.745 
(95% CI 0.668–0.822) to 0.768 (0.686–0.850), and in 
relation to all-cause mortality, the AUC increased from 
0.743 (0.644–0.843) to 0.803 (0.713–0.893) after adding 
SDMA to the model including traditional risk factors. 
As shown in Fig. 2c for decline in eGFR >30% the AUC 
increased from 0.722 (0.631–0.813) to 0.752 (0.664–
0.840). Increase in AUC (c statistic) quantifies the model’s 
improved ability to discriminate events from non-events. 
In simpler terms, if the model including SDMA on top of 
traditional risk factors is more likely to assign higher risk 
to persons with events. These changes in the AUC were 
all non-significant (p  ≥  0.10). Pencina et  al. [22] have 
described how AUC does not change materially even for 
powerful predictors and the increase in AUC is directly 
Table 1 Clinical characteristics of  the study population at  baseline categorized according to  SDMA and  ADMA values 
below or above the median
p values for differences between participants with symmetric and asymmetric dimethylarginine below or above the median
Italic values indicate significance of p value (p < 0.05)
eGFR estimated glomerular filtration rate, RAAS renin-angiotensin-aldosterone system
Characteristics All participants 
(n = 200)
Symmetric dimethylarginine p value Asymmetric dimethylarginine p value
<0.4525 µmol/l 
(n = 100)
≥0.4525 µmol/l 
(n = 100)
<0.4625 µmol/l 
(n = 100)
≥0.4625 µmol/l 
(n = 100)
Male, n (%) 152 (76) 76 (76) 75 (75) 0.87 77 (23) 74 (74) 0.62
Age (years) 59 ± 9 56.4 ± 9.2 60.9 ± 7.6 <0.001 57.2 ± 9.8 60.1 ± 7.3 0.015
Known duration of 
diabetes (years)
13 ± 7 10.8 ± 6.6 14.8 ± 7.6 <0.001 11.7 ± 7.3 13.9 ± 7.3 0.033
Body mass index 
(kg/m2)
32.6 ± 5.8 33.0 ± 5.3 32.1 ± 6.2 0.24 32.3 ± 4.8 32.8 ± 6.6 0.48
HbA1c (%) 7.9 ± 1.3 7.93 ± 1.36 7.80 ± 1.34 0.49 7.92 ± 1.41 7.81 ± 1.29 0.55
HbA1c (mmol/mol) 63 ± 14 63 ± 14.9 62 ± 14.6 0.49 63 ± 15.4 62 ± 14.1 0.55
Urinary albumin 
excretion rate 
(mg/24‑h)
103 (39–230) 104.5 (47.9–219.8) 98.0 (38.0–241.0) 0.86 80.5 (33.0–176.9) 133.0 (56.0–303.0) 0.011
P‑creatinine 
(μmol/L)
76 ± 18 67.0 ± 13.8 85.9 ± 17.4 <0.001 72.0 ± 17.4 80.9 ± 18.2 <0.001
eGFR (ml/
min/1.73 m2)
130 ± 17 99.3 ± 13.0 79.7 ± 15.6 <0.001 94.6 ± 16.9 84.4 ± 16.3 <0.001
Systolic blood  
pressure (mmHg)
152 ± 76 133 ± 18 127 ± 16 0.012 130 ± 17 130 ± 17 0.60
Diastolic blood 
pressure (mmHg)
75 ± 11 77 ± 11 73 ± 11 0.016 76 ± 11 73 ± 11 0.051
LDL cholesterol 
(mmol/L)
1.85 ± 0.78 1.90 ± 0.88 1.81 ± 0.67 0.39 1.81 ± 0.78 1.90 ± 0.78 0.45
Current 
smoker, n (%)
59 (30) 34 (34) 25 (25) 0.16 31 (31) 28 (28) 0.64
Treatment with
 Oral antidiabetic, 
n (%)
170 (85) 87 (87) 83 (83) 0.43 89 (89) 81 (81) 0.11
 Insulin, n (%) 124 (62) 58 (58) 66 (66) 0.24 59 (59) 65 (65) 0.38
 Antihypertensive 
drugs, n (%)
198 (99) 100 (100) 98 (98) 0.16 99 (99) 99 (99) 1.00
 RAAS blockade, 
n (%)
196 (98) 96 (96) 100 (100) 0.043 98 (98) 98 (98) 1.00
 Beta‑blocker, n (%) 27 (14) 9 (9) 18 (18) 0.063 11 (11) 16 (16) 0.31
 Calcium channel 
blockers, n (%)
80 (40) 43 (43) 37 (37) 0.39 36 (36) 44 (44) 0.25
 Diuretics, n (%) 128 (64) 57 (57) 41 (41) 0.039 63 (63) 65 (65) 0.77
 Statin, n (%) 189 (95) 94 (94) 95 (95) 0.76 97 (97) 92 (92) 0.12
 Aspirin, n (%) 183 (92) 92 (92) 91 (91) 0.80 90 (90) 93 (93) 0.45
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affected by the robustness of the baseline model. IDI sta-
tistics have been suggested by Pencina to further evaluate 
the incremental contribution of a new biomarker. rIDI 
quantifies the increase in separation of events and non-
events on a relative scale. The rIDI was 15.0% (p = 0.081) 
for the cardiovascular endpoint, 52.5% (p  =  0.025) for 
all-cause mortality and 48.8% (p =  0.007) for decline in 
eGFR >30%.
The cumulative incidence of decline in eGFR was 
higher in participants with SDMA level above the median 
(p =  0.0003; Additional file  1: Figure S2 panel c). How-
ever, the cumulative incidence of cardiovascular disease 
and all-cause mortality was similar in participants with 
SDMA level above or below the median (p ≥ 0.098; Addi-
tional file 1: Figure S2 panel a and b).
Asymmetric dimethylarginine as a risk marker
Table 2 shows the association between ADMA and car-
diovascular disease, all-cause mortality, and decline in 
eGFR. In unadjusted analysis, higher ADMA was asso-
ciated with all-cause mortality (p = 0.002), but not with 
cardiovascular disease (p  =  0.38) or decline in eGFR 
>30% (p = 0.29). The association between ADMA and all-
cause mortality persisted after adjustment for traditional 
risk factors (p = 0.006). As shown in Fig. 2d when add-
ing ADMA to traditional risk factors the AUC increased 
from 0.743 (95% CI 0.644–0.843) to 0.794 (0.699–0.889) 
in relation to all-cause mortality. The change was non-
significant (p  =  0.11). The rIDI for ADMA was 49.1% 
(p = 0.017) for all-cause mortality.
The cumulative incidence of all-cause mortality was 
similar in participants with ADMA level above or below 
the median (p = 0.74; Additional file 1: Figure S2 panel 
d).
Discussion
In our cohort of 200 persons with type 2 diabetes and 
microalbuminuria, we demonstrated higher SDMA to be 
an independent determinant of incident cardiovascular 
disease, all-cause mortality and decline in renal function. 
We further demonstrated higher ADMA to be associated 
with all-cause mortality after adjustment for traditional 
risk factors, while ADMA was not associated with inci-
dent cardiovascular disease and decline in renal function. 
When applying c statistics, SDMA and ADMA respec-
tively added to traditional risk factors did not signifi-
cantly increase the risk prediction. IDI statistics has been 
suggested by Pencina as a necessary and more powerful 
method going beyond statistical significance and c sta-
tistic to evaluate the incremental contribution of a new 
biomarker [22]. We demonstrated added predictive value 
using IDI statistics for all-cause mortality after addition 
of SDMA and ADMA, respectively; and for decline in 
renal function adding SDMA to traditional risk factors.
Symmetric dimethylarginine is without direct inhibi-
tory effect on nitric oxide synthesis and has therefore 
been given little attention compared to ADMA [12]. 
We are only aware of two studies that have investigated 
the association of SDMA to incident cardiovascular 
disease in persons with type 2 diabetes. In 270 persons 
with type 2 diabetes Hsu et  al. [23] reported elevated 
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Fig. 1 Correlation between symmetric and asymmetric dimethylar‑
ginine
Table 2 Biomarkers in relation to risk of fatal and nonfatal cardiovascular events, all-cause mortality and decline in eGFR 
>30%
Values are hazard ratios with 95% confidence intervals, and represent 1 SD increment of log-transformed values of the biomarkers. Adjustment included sex, age, 
systolic blood pressure, LDL cholesterol, smoking,  HbA1c, plasma creatinine, and urinary albumin excretion rate
Italic values indicate significance of p value (p < 0.05)
eGFR estimated glomerular filtration rate
Biomarker Model Cardiovascular 
events (n = 40)
p All‑cause mortality 
(n = 26)
p Decline in eGFR > 30% 
(n = 42)
p
Symmetric dimethylarginine log 
scale (1 SD = 0.06)
Unadjusted 1.5 (1.2–1.9) 0.001 1.6 (1.2–2.1) 0.001 1.9 (1.3–2.6) <0.001
Adjusted 1.7 (1.1–2.6) 0.019 2.3 (1.4–3.9) 0.001 2.2 (1.4–3.7) 0.002
Asymmetric dimethylarginine log 
scale (1 SD = 0.13)
Unadjusted 1.2 (0.8–1.6) 0.38 1.7 (1.2–2.5) 0.002 1.2 (0.8–1.6) 0.29
Adjusted 1.0 (0.7–1.5) 0.93 1.8 (1.2–2.7) 0.006 1.0 (0.7–1.4) 0.85
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SDMA to predict risk of cardiovascular events (car-
diovascular death, non-fatal myocardial infarction and 
stroke) in univariate analysis, but significance was lost 
after adjustment. Median follow-up was 5.7  years. A 
recent study by Anderssohn et  al. reported an associa-
tion of SDMA with prevalent cardiovascular disease in 
783 older persons with type 2 diabetes. This association 
lost significance after adjusting for age, sex and renal 
c
AUC
(95% CI)
p-value
Panel a: composite cardiovascular disease endpoint
Base model 0.745 (0.668, 0.822) 0.24Base model + symmetric dimethylarginine 0.768 (0.686, 0.850)
Panel b: all-cause mortality
Base model 0.743 (0.644, 0.843) 0.10Base model + symmetric dimethylarginine 0.803 (0.713, 0.893)
Panel c: deterioration in kidney function
Base model 0.722 (0.631, 0.813) 0.16Base model + symmetric dimethylarginine 0.752 (0.664, 0.840)
Panel d: all-cause mortality
Base model 0.743 (0.644, 0.843) 0.11Base model + asymmetric dimethylarginine 0.794 (0.699, 0.889)
Fig. 2 Receiver operating characteristic (ROC) curves. Base model includes sex, age, systolic blood pressure, LDL‑cholesterol, smoking,  HbA1c, 
creatinine and urinary albumin excretion rate. Dashed line reference; Dotted line Base model; Full line Base model + symmetric dimethylarginine/
asymmetric dimethylarginine
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function. After 4 years of follow-up SDMA was not sig-
nificantly associated with risk of incident coronary artery 
or cerebrovascular disease [9]. In our cohort we showed 
an association between higher SDMA and incident car-
diovascular disease, all-cause mortality as well as dete-
rioration in kidney function. SDMA has emerged as a 
marker of renal disease and in contrast to ADMA which 
is cleared mainly through enzymatic action [24], SDMA 
is almost completely excreted by the kidneys [25]. Lev-
els of SDMA have previously been shown to be closely 
related to glomerular filtration rate in a cross-sectional 
study in persons with coronary artery disease [26]. This 
relation was confirmed in the present study, where high 
levels of SDMA were associated with lower levels of 
eGFR at baseline. Importantly, in our cohort SDMA 
was associated with deterioration in kidney function 
after adjustment for kidney function at baseline. Besides 
the strong correlation with renal function, the underly-
ing mechanism of SDMA as a marker of risk in diabetes 
could potentially be explained by a pro-inflammatory 
effect. Where ADMA directly inhibits the production of 
nitric oxide by interfering with the nitric oxide synthase, 
SDMA acts as a competitor of l-arginine, the substrate 
for nitric oxide synthase. This ultimately leads to an 
increased endothelial production of reactive oxygen spe-
cies [26, 27] and this pro-inflammatory effect of SDMA 
may trigger vascular pathology. We demonstrated a mod-
erate correlation between SDMA and ADMA. However, 
the relationship between SDMA and ADMA may not be 
straightforward and they may reflect different aspects of 
pathophysiology. We suggest SDMA as a promising new 
marker of endothelial dysfunction and inflammation with 
the potential to improve risk prediction in persons with 
type 2 diabetes and microalbuminuria.
The lack of association between ADMA and inci-
dent cardiovascular disease is in contrast to a number 
of previous studies. However, the prospective studies 
of ADMA in type 2 diabetes have mainly included sub-
jects at high cardiovascular risk including manifest car-
diovascular disease [23, 28–30]. Krzyzanowska et  al. 
demonstrated an independent association between high 
ADMA and manifest cardiovascular disease (myocardial 
infarction, percutaneous coronary intervention, coro-
nary-artery bypass graft, stroke, carotid revascularization 
and all-cause mortality) in 125 participants with type 2 
diabetes after a median follow-up of 21  months [tertile 
III vs tertile I: HR 2.37 (95% CI 1.05–5.35), p  =  0.038] 
[29]. Of the 125 participants, 40% had a history of mac-
rovascular disease. Hsu et  al. reported elevated ADMA 
to predict risk of cardiovascular events when analyzed 
both as categorical [tertile III vs tertile I: HR 2.3 (95% 
CI 1.1–4.8), p =  0.026] and as continuous variable [per 
1 SD (0.09 µmol/l) increase HR: 1.30 (95% CI 1.01–1.68), 
p =  0.04] after appropriate adjustment [23]. 78% of the 
participants had concomitant coronary artery disease 
at baseline. Cavusoglu et  al. reported elevated levels of 
ADMA to be independently associated with an increased 
risk of cardiovascular outcomes at 2-years of follow-up in 
high-risk type 2 diabetic males with known or suspected 
coronary artery disease referred for coronary angiog-
raphy [tertile III vs tertile I–II: composite outcome of 
all-cause mortality, myocardial infarction or stroke HR 
2.00 (1.10–3.62), p =  0.02] [30]. In contrast, two larger 
studies, the Framingham Offspring study enrolling 3320 
participants (372 with diabetes) and a study in 997 indi-
viduals (359 with diabetes) referred for coronary angiog-
raphy demonstrated higher ADMA to be associated with 
cardiovascular events and all-cause mortality only in the 
participants without diabetes at baseline [10, 31]. In the 
study including 783 older persons with type 2 diabetes, 
the association between higher ADMA and prevalent 
cardiovascular disease lost significance after adjustment 
for age, sex and renal function, and in the prospective 
analysis ADMA was not associated with incident coro-
nary artery or cerebrovascular disease [9].
There is some evidence that both glycaemic control 
and nephropathy status may directly affect ADMA lev-
els [23, 32, 33]. Therefore, ADMA levels may change 
with progression of disease and complications status 
and the prognostic value of ADMA in persons with dia-
betes could therefore be highly dependent on the study 
population investigated. This could explain the conflict-
ing results concerning the prognostic value of ADMA 
for cardiovascular complications in type 2 diabetes. Our 
study population differs from previous studies as we 
excluded participants with a history of or symptoms sug-
gestive of coronary artery disease. In contrast we did find 
a relation to all-cause mortality. This is in accordance 
with findings in the aforementioned study by Cavusoglu 
et al. [tertile III vs tertile I–II: all-cause mortality HR 2.63 
(1.13–6.11), p = 0.03] [30]. Other authors have included 
all-cause mortality in a combined cardiovascular end-
point and reported positive associations [29].
The ratio of SDMA/ADMA has been suggested as a 
predictive biomarker for decline in renal function in per-
sons with type 2 diabetes [14]. In our study the SDMA/
ADMA ratio was associated with all-cause mortality 
(p = 0.039), but not with cardiovascular disease or deteri-
oration in kidney function (p ≥ 0.12) in analysis adjusted 
for traditional risk factors.
Clinical implications
We demonstrate that the addition of SDMA to tradi-
tional risk factors improved risk prediction for all-cause 
mortality and decline in renal function and our findings 
illustrate that SDMA may be useful in the risk assessment 
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of persons with type 2 diabetes. However, evidence sug-
gests that the role of both SDMA and ADMA in diabe-
tes is complex and not completely understood. Therefore, 
further research is needed in type 2 diabetic subjects at 
different risk of cardiovascular and renal disease to fur-
ther elucidate the role of the two dimethylarginines.
Study limitations
The main limitation is the relatively small sample size. 
Moreover, it is important to consider that we included 
persons with type 2 diabetes and microalbuminuria 
recruited from a single center, limiting the generalisation 
of our results. For both SDMA and ADMA we report 
non-significant improvements in risk prediction evalu-
ated with c statistics. However, we demonstrated added 
predictive value using IDI statistics. It remains a chal-
lenge to establish the ranges of meaningful improvement 
for IDI and the clinical value of ADMA and SDMA as 
risk markers remains to be evaluated in interventions 
studies.
Conclusion
In a well-characterized population with type 2 diabetes, 
microalbuminuria and without a history or symptoms 
suggestive of coronary artery disease, higher SDMA 
was associated with incident cardiovascular disease, all-
cause mortality and deterioration in renal function, and 
improved risk prediction for all-cause mortality and renal 
decline beyond traditional risk factors. Higher ADMA 
improved risk prediction for all-cause mortality beyond 
traditional risk factors.
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